Fragile X Syndrome: Lessons Learned and What New Treatment Avenues Are on the Horizon
- 6 January 2022
- journal article
- review article
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 62 (1), 365-381
- https://doi.org/10.1146/annurev-pharmtox-052120-090147
Abstract
Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading single-gene form of autism spectrum disorder, encompassing cognitive, behavioral, and physical forms of clinical involvement. FXS is caused by large expansions of a noncoding CGG repeat (>200 repeats) in the FMR1 gene, at which point the gene is generally silenced. Absence of FMR1 protein (FMRP), important for synaptic development and maintenance, gives rise to the neurodevelopmental disorder. There is, at present, no therapeutic approach that directly reverses the loss of FMRP; however, there is an increasing number of potential treatments that target the pathways dysregulated in FXS, including those that address the enhanced activity of the mGluR5 pathway and deficits in GABA pathways. Based on studies of targeted therapeutics to date, the prospects are good for one or more effective therapies for FXS in the near future. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 62 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.Keywords
This publication has 106 references indexed in Scilit:
- Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinaseDisease Models & Mechanisms, 2011
- FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and AutismCell, 2011
- Reversible Inhibition of PSD-95 mRNA Translation by miR-125a, FMRP Phosphorylation, and mGluR SignalingMolecular Cell, 2011
- Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia PatientsNeuropsychopharmacology, 2011
- Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterizationJournal of Neurodevelopmental Disorders, 2010
- Aripiprazole in Autism Spectrum Disorders and Fragile X SyndromeNeurotherapeutics, 2010
- A Novel Function for Fragile X Mental Retardation Protein in Translational ActivationPLoS Biology, 2009
- Autism Profiles of Males With Fragile X SyndromeAmerican Journal on Mental Retardation, 2008
- The Cyclic AMP Cascade Is Altered in the Fragile X Nervous SystemPLOS ONE, 2007
- The mGluR theory of fragile X mental retardationTrends in Neurosciences, 2004